Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 15/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.45 |
| ▸ | HRH1 | P35367 | 3/20 | 0.42 |
| ▸ | HRH2 | P25021 | 2/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4398537 | 0.91 | HRH4 (0.54) | HRH4HRH3KCNH2 | |
| SCHEMBL4394799 | 0.91 | HRH4 (0.54) | HRH4HRH3KCNH2 | |
| SCHEMBL4391935 | 0.86 | DHFR (0.51) | HRH4HRH3KCNH2DHFR | |
| SCHEMBL4388710 | 0.85 | HRH4 (0.46) | HRH4HRH3KCNH2HRH1HRH2 | |
| SCHEMBL4399752 | 0.85 | HRH4 (0.46) | HRH4HRH3KCNH2HRH1HRH2 | |
| SCHEMBL4390834 | 0.84 | HRH4 (0.45) | HRH4HRH3KCNH2HRH1HRH2 | |
| SCHEMBL4398505 | 0.84 | HRH4 (0.59) | HRH4HRH3KCNH2HRH1HRH2 | |
| SCHEMBL4396098 | 0.83 | HRH4 (0.44) | HRH4HRH3KCNH2HRH1HRH2 | |
| SCHEMBL4393790 | 0.83 | HRH4 (0.44) | HRH4HRH3KCNH2HRH1HRH2 | |
| SCHEMBL4398527 | 0.82 | HRH4 (0.43) | HRH4HRH3KCNH2HRH1HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306038-A1 | 2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity | PALAU PHARMA, S.A. (ES) | 2009-12-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306038-A1 | 2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity | HRH4, HRH2, HRH3 | HRH4 1/4885HRH3 3/4885KCNH2 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.